Answers are grounded in this paper and cite their sources.
We report the dosimetric evaluation of prostate-specific membrane antigen–based radioligand therapy (RLT) for metastatic prostate cancer in a patient with autosomal-dominant polycystic kidney disease. Methods: The patient received hemodialysis during each of 6 RLT cycles while staying as an inpatient. We used voxel dosimetry and blood sampling for the dose calculation. Results: The patient responded well to the RLT, as indicated by the prostate-specific antigen level decreasing from 298 to 7.1 ng/mL. The doses per cycle ranged from 0.19 to 0.4 Gy/GBq for the parotid gland, 0.14 to 0.28 Gy/GBq for the submandibular gland, 0.03 to 0.11 Gy/GBq per kidney, and 0.10 to 0.15 Gy/GBq for the red bone marrow. Conclusion: This case suggests that [177Lu]Lu-PSMA–based RLT can be applied successfully and safely to a patient with chronic kidney disease undergoing hemodialysis.
No takes yet. Share an insight, caveat, or question.
Mercolli et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: